-
×
Tesamorelin 10mg
1 × $145.00
Subtotal: $145.00
Tirzepatide 30mg
$195.00
Tirzepatide 30 mg is a ≥ 99 % pure dual-receptor peptide supplied as a lyophilized
powder for in-vitro GLP-1 / GIP research. For laboratory use only—no human
or veterinary applications.
Tirzepatide is a synthetic peptide under investigation for concurrent
agonist activity at GLP-1 and
GIP receptors.
Ongoing in-vitro studies explore dual-receptor signalling pathways
relevant to metabolic research models.
Specification
- Peptide Name: Tirzepatide
- Content: 30 mg lyophilized powder (requires reconstitution)
- Purity: ≥ 99 % (HPLC / MS certificate available)
- Manufacturing: ISO 9001:2015 & cGMP-audited facility
- Intended Use: In-vitro laboratory research only
Storage & Handling
- Prior to reconstitution: store ≤ 8 °C in a dry environment
- After reconstitution: refrigerate 2 – 8 °C and use within 30 days
- For extended preservation: aliquot and freeze at −20 °C
- Avoid repeated freeze–thaw cycles
Compliance Notice
Supplied exclusively to qualified professionals for controlled laboratory
applications. No dosage or administration guidance is provided. Buyer assumes
responsibility for safe handling and regulatory adherence.
Description
Tirzepatide 30mg is an innovative dual-action peptide medication specifically formulated for the management of type 2 diabetes. This advanced therapy represents a significant breakthrough in diabetes treatment by combining the effects of two critical incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By targeting these pathways, Tirzepatide effectively regulates blood glucose levels and supports weight loss, addressing key components of type 2 diabetes management.
Mechanism of Action
Tirzepatide operates through a multifaceted approach:
- GLP-1 Receptor Agonism: By activating GLP-1 receptors, Tirzepatide enhances insulin secretion in response to meals, which helps lower blood sugar levels. It also suppresses glucagon release, further contributing to glycemic control.
- GIP Receptor Agonism: The action on GIP receptors enhances the body’s insulin response and improves lipid metabolism, providing additional benefits for weight management.
- Appetite Regulation: Tirzepatide slows gastric emptying, leading to increased satiety and reduced food intake. This mechanism is particularly beneficial for individuals looking to lose weight alongside managing their diabetes.
Clinical Benefits
- Effective Glycemic Control: Clinical trials have shown that Tirzepatide significantly reduces HbA1c levels, leading to improved long-term blood sugar management for patients.
- Weight Loss: Many patients using Tirzepatide experience substantial weight reduction, which is crucial for managing type 2 diabetes and mitigating associated health risks, such as cardiovascular disease.
- Enhanced Metabolic Health: By improving insulin sensitivity and supporting weight loss, Tirzepatide contributes to better overall metabolic health, which is vital for individuals with type 2 diabetes.
- Convenient Administration: The medication is administered via subcutaneous injection once weekly, making it a convenient option that enhances patient adherence to treatment.
Side Effects and Considerations
While Tirzepatide is generally well-tolerated, potential side effects may include nausea, vomiting, diarrhea, and injection site reactions. Most side effects are mild to moderate and often decrease over time. Patients should discuss their complete medical history and any other medications with their healthcare provider to ensure that Tirzepatide is suitable for their treatment plan.
Conclusion
Tirzepatide 30mg represents a significant advancement in the management of type 2 diabetes, offering a comprehensive solution by effectively combining the beneficial effects of GLP-1 and GIP. With its ability to improve glycemic control and support weight loss, Tirzepatide stands out as a promising therapeutic option for individuals seeking to manage their diabetes effectively. As the landscape of diabetes treatment continues to evolve, Tirzepatide offers hope for better health outcomes and improved quality of life for patients.
Related products
-
Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)
$175.00Size: 12mg Contents: Fragment 176-191 (6mg), CJC-1295 NO DAC (3mg), Ipamorelin (3mg) Form: Lyophilized powder Purity: >99% -
Tirzepatide 60mg
Tirzepatide is a synthetic peptide under investigation for concurrent agonist activity at GLP-1 and GIP receptors. Ongoing in-vitro studies explore dual-receptor signaling pathways relevant to metabolic research models.Specification
- Peptide Name: Tirzepatide
- Content: 60 mg lyophilized powder (requires reconstitution)
- Purity: ≥ 99 % (HPLC / MS certificate available)
- Manufacturing: ISO 9001:2015 & cGMP-audited facility
- Intended Use: In-vitro laboratory research only
Storage & Handling
- Prior to reconstitution: store ≤ 8 °C in a dry environment
- After reconstitution: refrigerate 2 – 8 °C and use within 30 days
- For extended preservation: aliquot and freeze at −20 °C
- Avoid repeated freeze–thaw cycles
Compliance Notice
Supplied exclusively to qualified professionals for controlled laboratory applications. No dosage or administration guidance is provided. Buyer assumes responsibility for safe handling and regulatory adherence. $300.00 -
Reta/Cagri Blend – 12.5mg/2.5mg
Reta/Cagri Blend – 12.5mg/2.5mg is a combination therapeutic agent designed for weight management and metabolic improvement. This blend combines Retatrutide, which regulates appetite and enhances energy expenditure, with Cagri, known for its role in metabolic processes.Benefits:
- Effective Weight Loss: The synergistic action of both components aids in achieving substantial weight loss.
- Improved Metabolic Function: Enhances overall metabolic health, supporting better energy utilization.
- Convenient Administration: Administered via subcutaneous injection, making it easy for self-administration.
-
Tesamorelin 10mg
Tesamorelin 10 mg is a ≥ 99 % pure GHRH-analog peptide supplied as a lyophilized powder for in-vitro growth-hormone pathway research. For laboratory use only—no human or veterinary applications. Tesamorelin 10mg is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate the production of growth hormone (GH) from the pituitary gland. It is primarily used in the management of lipodystrophy in HIV-infected patients, helping to reduce excess abdominal fat. Administered via subcutaneous injection, Tesamorelin promotes improved body composition and metabolic health.Benefits:
- Reduction of Abdominal Fat: Effectively targets and reduces visceral fat.
- Improved Body Composition: Enhances lean muscle mass and overall metabolic profile.
- Convenient Administration: Easy self-injection for patient convenience.
Reviews
There are no reviews yet.